| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Other Events
As previously disclosed in Part II, Item 1 of the Quarterly Report on Form 10-Q filed by Skye Bioscience, Inc. (the “Company”) with the Securities and Exchange Commission on August 14, 2026, a former employee of the Company filed a lawsu... |
| 11 Sep 2026 |
8-K: Termination of a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Company provided writ... |
| 24 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[***]”)... |
| 19 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 18, 2026, Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the ... |
| 14 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +5 more
***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[***]”)... |
| 23 Jun 2026 |
8-K: Other Events
As previously disclosed on a Current Report on Form 8-K filed by Skye Bioscience, Inc. (the “Company”) on May 13, 2026, the Company received a written notification from the Listing Qualifications Department (the “Staff”) of The Nasdaq St... |
| 29 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Name of entity as on file with the Nevada Secretary of State: |
| 15 May 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On May 13, 2026, Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quar... |
| 03 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Master Services Agreement (this “Agreement”) is entered into as of March 31, 2026 (the “Effective Date”), by and between Lohman & Associates, Inc., a California corporation (“L&A”), and Skye Bioscience, Inc. a Nevada corporation (“C... |
| 19 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On March 17, 2026, Skye Bioscience, Inc. (the “Company” or “Skye”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the... |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, CA, March 10, 2026 -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, ... |
| 20 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On February 13, 2026, the Company and Kaitlyn Arsenault determined that Ms. Arsenault will step down from her position as Chief Financial Officer of the Company, effective February 20, 2026 (the “Separation Date”) to pursue new professio... |
| 02 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases February 2026 Nasdaq: SKYE |
| 23 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
On December 18, 2025, Skye Bioscience, Inc. (the “Company”) entered into a Non-exclusive Collaboration and License Agreement (the “Agreement”) with Halozyme, Inc. (“Halozyme”). |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, CA, November 10, 2025 -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, o... |
| 06 Oct 2025 |
8-K: Regulation FD Disclosure
SAN DIEGO, CA – October 6, 2025 – Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the to... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, CA, August 7, 2025 -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, over... |
| 11 Jun 2025 |
8-K: Changes in Registrant's Certifying Accountant; Submission of Matters to a Vote of Security Holders
We have read the statements made by Skye Bioscience, Inc. under Item 4.01 of its Form 8-K dated June 11, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other st... |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, CA, May 8, 2025 -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overwei... |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, CA, March 20, 2025 -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, ... |
Loading...